UK National Screening Committee position statement on surrogate outcomes in cancer screening trials.
Level V
Where this comes from
- Record sourced from PubMed, PMID 42185047.
- Also identified by DOI 10.1136/bmj-2026-629407 and PMC identifier 13224044.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Surrogate outcomes may offer earlier evidence of benefit and initiate further evaluative work, but they cannot yet replace mortality as the definitive outcome in cancer screening trials, say <b>Sian Taylor-Phillips and colleagues</b>